Wakelee, Heather A.

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine

Cancer Genomics and DiagnosticsPrenatal Screening and Diagnostics

Cited by 2,220

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S.-H., Gao, S., Chen, K.-N., Dooms, C., Majem, M., Eigendorff, E., et al. (2023) · New England Journal of Medicine

Lung Cancer Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 1,180

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

Rolfo, C., Mack, P., Scagliotti, G. V., Aggarwal, C., Arcila, M. E., Barlesi, F., Bivona, T., Diehn, M., Dive, C., Dziadziuszko, R., et al. (2021) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 683

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

Sequist, L. V., Soria, J.-C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Papadimitrakopoulou, V., Solomon, B. J., Oxnard, G. R., Dziadziuszko, R., et al. (2015) · New England Journal of Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 665

EGFR -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

Marcoux, N., Gettinger, S. N., O’Kane, G., Arbour, K. C., Neal, J. W., Husain, H., Evans, T. L., Brahmer, J. R., Muzikansky, A., Bonomi, P. D., et al. (2019) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 500

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

Reckamp, K. L., Melnikova, V. O., Karlovich, C., Sequist, L. V., Camidge, D. R., Wakelee, H., Perol, M., Oxnard, G. R., Kosco, K., Croucher, P., et al. (2016) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 287

Scientific Advances in Lung Cancer 2015

Tsao, A. S., Scagliotti, G. V., Bunn, P. A., Carbone, D. P., Warren, G. W., Bai, C., de Koning, H. J., Yousaf-Khan, A. U., McWilliams, A., Tsao, M. S., et al. (2016) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 284

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Negrao, M. V., Araujo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M., Minuti, G., et al. (2023) · Cancer Discovery

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 203

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Galan-Cobo, A., Le, J. T., Montesion, M., Palmer, R., Jahchan, N., et al. (2024) · Nature

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 194

Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor–Induced Myocarditis

Zhu, H., Galdos, F. X., Lee, D., Waliany, S., Huang, Y. V., Ryan, J., Dang, K., Neal, J. W., Wakelee, H. A., Reddy, S. A., et al. (2022) · Circulation

Cancer Immunotherapy and BiomarkersViral Infections and Immunology Research

Cited by 192

Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips

Earhart, C. M., Hughes, C. E., Gaster, R. S., Ooi, C. C., Wilson, R. J., Zhou, L. Y., Humke, E. W., Xu, L., Wong, D. J., Willingham, S. B., et al. (2014) · Lab Chip

Microfluidic and Bio-sensing TechnologiesMicrofluidic and Capillary Electrophoresis Applications

Cited by 165

Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery

Chiou, S.-H., Tseng, D., Reuben, A., Mallajosyula, V., Molina, I. S., Conley, S., Wilhelmy, J., McSween, A. M., Yang, X., Nishimiya, D., et al. (2021) · Immunity

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 133

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

Saad, M. B., Hong, L., Aminu, M., Vokes, N. I., Chen, P., Salehjahromi, M., Qin, K., Sujit, S. J., Lu, X., Young, E., et al. (2023) · The Lancet Digital Health

Radiomics and Machine Learning in Medical ImagingCancer Immunotherapy and Biomarkers

Cited by 121

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

Papadopoulos, K. P., Borazanci, E., Shaw, A. T., Katayama, R., Shimizu, Y., Zhu, V. W., Sun, T. Y., Wakelee, H. A., Madison, R., Schrock, A. B., et al. (2020) · Clinical Cancer Research

Lung Cancer Treatments and MutationsCancer Mechanisms and Therapy

Cited by 113

Metabolic Tumor Volume is an Independent Prognostic Factor in Patients Treated Definitively for Non–Small-Cell Lung Cancer

Lee, P., Bazan, J. G., Lavori, P. W., Weerasuriya, D. K., Quon, A., Le, Q.-T., Wakelee, H. A., Graves, E. E., & Loo, B. W. (2012) · Clinical Lung Cancer

Lung Cancer Diagnosis and TreatmentMedical Imaging Techniques and Applications

Cited by 92

10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer

Soria, J., Sequist, L. V., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Yu, H. A., Solomon, B. J., Ou, S. H., Papadimitrakopoulou, V., et al. (2014) · European Journal of Cancer

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 5